Oncopharmpod
HER3-DXd & Motixafortide
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:16
- Mas informaciones
Informações:
Sinopsis
An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).
